|Bid||15.69 x 1000|
|Ask||18.61 x 100|
|Day's Range||17.15 - 17.97|
|52 Week Range||13.01 - 19.62|
|PE Ratio (TTM)||-13.16|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||26.67|
THE WOODLANDS, Texas, June 19, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that XERMELO™ (telotristat ethyl) 250 mg has been included as a recommended treatment option in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for neuroendocrine tumors (NET) patients with carcinoid syndrome diarrhea. The NCCN designated XERMELO together with somatostatin analog (SSA) therapy as a category 2A treatment for adults inadequately controlled by SSA therapy.
Jounce Therapeutics, Lexicon Pharmaceuticals, and Paratek Pharmaceuticals might be three hidden gems in the healthcare sector worth checking out.
Here's why shares of Kite Pharma, bluebird bio, and Lexicon Pharmaceuticals shot higher this past week.